Screener / SEC EDGAR /CIK 0001830033 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq, OTC Materials · Plastics & Resins

PureCycle Technologies, Inc. PCT

Compare with peers Embed
The 10-K against last year's

274 changes: 47 added, 139 removed, 85 reworded, 3 quiet changes

10-K Feb 26, 2026 vs Feb 27, 2025

10-K 0001193125-26-076801 (Feb 26, 2026) vs 10-K 0000950170-25-028422 (Feb 27, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

93 paragraphs · 11 new · 64 reworded · 8 gone · 10-K Feb 26, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 15 · 49% changed Every version of it
Construction If PCT is unable to consistently execute capital investment projects to cost, schedule and operability targets, the Company's reputation, economic viability and ability to raise capital could be impacted, and construction of one or more additional pre-processing PreP and purification Purification facilities may be delayed or abandoned.
Paragraph 2 · 48% changed Every version of it
PCT’s ability to be profitable in PCT is a low-revenue early commercial-stage company, and may never achieve or sustain profitability, which depends on the future will depend on PCT’s ability to successfully commercialize PureFive™ successful commercialization and scale-up of PureFive® resin products, and any other products PCT may develop in the future, to scale in the United States, U.S., Europe and beyond.
Paragraph 76 · 47% changed Every version of it
The various regulatory schemes applicable to PCT’s PureFive™ resin will continue to apply following initial approval. Monitoring regulatory changes and ensuring our ongoing compliance with applicable requirements is time-consuming and may affect PCT’s business, financial condition, results of operation and prospects. If PCT fails to comply with such requirements on an ongoing basis, PCT may be subject to fines or other penalties, or may be prevented from selling PureFive™ PureFive® resin products, and PCT’s business, financial condition, results of operation and prospects may be harmed.
Paragraph 11 · 47% changed Every version of it
PCT requires will require additional financing to fund its operations and growth. The failure to secure There can be no assurance that additional financing could have a material adverse effect capital will be available when needed, on acceptable terms or at all. Any such financing, if available, may involve the continued development and growth of PCT. Such financings may result in dilution to stockholders, issuance of equity or equity-linked securities that are dilutive to existing stockholders, securities with priority as preferences that are senior to liquidation and dividend and other rights more favorable than common stock, imposition of debt covenants and the Company's Common Stock, or additional indebtedness that imposes restrictive covenants, collateral requirements, or repayment obligations, or other restrictions that may adversely affect its business. In addition, each of which could further constrain PCT’s operations and liquidity. PCT may also seek additional capital opportunistically due to favorable market conditions or strategic considerations even if it believes that it has sufficient funds for current or future operating plans. There can be no assurance that financing will be available to existing resources are adequate. If PCT on favorable terms, or at all. The inability to cannot obtain financing when needed required or on reasonable terms, it may make it more difficult for PCT be unable to operate execute its business strategy, meet obligations as they come due, or implement maintain compliance with financial covenants, any of which would adversely affect its growth plans. business, financial condition, results of operations and prospects.
Paragraph 7 · 45% changed Every version of it
Legislative, regulatory or judicial developments PCT’s substantial indebtedness, restrictive covenants, and potential inability to obtain additional financing could materially and adversely affect PCT’s its business, financial condition, results of operations and prospects.
Paragraph 8 · 41% changed Every version of it
As of December 31, 2024, 2025, PCT had total consolidated debt indebtedness of $346.6 $363.7 million, including notes bonds payable to related parties. PCT has not yet begun commercial operations parties and does not yet have any sources of material recurring revenue. PCT’s existing and future debt service obligations obligations, together with restrictions in its financing arrangements and the uncertainty of access to additional capital, could have important consequences to PCT for the foreseeable future, including the following: (i) PCT’s ability to obtain additional financing for capital expenditures, working capital or other general corporate purposes may be impaired; (ii) a substantial future. A significant portion of PCT’s cash flow from operating activities must activities, if and when generated, will be dedicated required to the payment of principal and interest on PCT’s service debt, thereby reducing the which will reduce funds available to us for PCT’s operations operations, capital expenditures, strategic initiatives, and other corporate purposes; and (iii) PCT purposes. PCT’s leverage may be or become substantially more leveraged than exceed that of some of its competitors, which may place PCT potentially placing it at a relative competitive disadvantage and make us more vulnerable to changes in market conditions and governmental regulations. increasing its
Paragraph 10 · 40% changed Every version of it
PCT is required to maintain compliance with certain financial and other covenants under its debt agreements. There are and will be operating and financial restrictions and covenants in certain of PCT’s debt agreements, including the Loan Agreement (as defined below), as well as and certain other agreements to which PCT is or may become a party. These limit, party, contain operating, financial covenants and other restrictions that, among other things, PCT’s or limit PCT and its subsidiaries’ ability to incur certain additional debt, create certain liens or other encumbrances, sell assets, and transfer ownership interests interests, pay dividends, and enter into transactions with affiliates of PCT. affiliates. These covenants limitations could also limit PCT’s ability to engage in restrict activities that may be in PCT’s best long-term interests. PCT’s failure, or perceived failure, interests and reduce its financial and operational flexibility. A failure to comply with certain covenants in these agreements could result in an Event event of Default (as defined therein) default under the various debt one or more agreements, allowing permitting lenders to accelerate the maturity for the debt under these agreements and to maturity, foreclose upon any on collateral securing the debt. An Event of Default would also adversely affect PCT’s ability to access its borrowing capacity debt, terminate commitments, or exercise other remedies. Cross-default provisions could compound these effects, and pay debt service on its outstanding debt, likely resulting in acceleration of such debt or in a default under other agreements containing cross-default provisions. Under such circumstances, PCT might not have sufficient funds or other resources to satisfy all of its obligations. In addition, the limitations imposed by PCT’s financing agreements on its ability to pay dividends, incur additional debt and to take other actions might significantly impair PCT’s ability to obtain other financing, generate sufficient cash flow from operations to enable PCT to pay its debt obligations or to fund other liquidity needs. Such consequences would adversely affect PCT’s business, financial condition, results of operations and prospects. refinance or restructure such indebtedness on favorable terms or at all.
Paragraph 17 · 35% changed Every version of it
The Additionally, the construction and commissioning of any new project, including pre-processing PreP and purification Purification facilities, is dependent on a number of contingencies, many of which are beyond PCT’s control. There is also a risk that significant unanticipated costs or delays could arise due to, among other things, errors or omissions, unanticipated or concealed construction site conditions, including subsurface conditions, unforeseen technical issues or increases in plant and equipment costs, insufficiency of water supply and other utility infrastructure, or inadequate contractual arrangements. Should significant unanticipated costs arise, this could have a material adverse impact on PCT’s business, financial performance and operations. No assurance can be given that construction will be completed, or will be completed without further delay.

MD&A

65 paragraphs · 36 new · 26 reworded · 131 gone · 10-K Feb 26, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 28 · 50% changed
The $381.2 interest income increase of $0.7 million decrease in net cash used in financing activities for the year ending ended December 31, 2025 as compared to the year ended December 31, 2024 compared to 2023 was primarily attributable to reductions the increase in the cash inflows balance as a result of $225.0 million the proceeds from debt offerings in 2023 and proceeds the issuance of $38.0 million from related party debt, and cash outflows the Series B Convertible Perpetual Preferred Stock during the second quarter of $253.2 million paid in 2024 to purchase the outstanding revenue bonds 2025, partially offset by $90 million in preferred transaction proceeds, $40 million from sale the liquidation of revenue bonds to related parties, and $8.0 million from issuance of revenue bonds our available-for-sale investment portfolio earlier during 2024.
Paragraph 14 · 49% changed
The Company’s Our FDA food contact grades are food-contact grade resins are, subject to certain conditions, capable of being used for all food types per the conditions of use COUs listed and per all applicable authorizations in the food contact regulations listed in the 21 CFR (Code of Federal Regulations, Title 21). regulations.
Paragraph 53 · 49% changed
The $381.2 million decrease in net cash used in Cash provided by financing activities for the year ending ended December 31, 2024 compared to 2023 2025 was primarily attributable to reductions comprised of $300.0 million of proceeds from the issuance of the Series B Convertible Perpetual Preferred Stock during the second quarter of 2025, $33.5 million of proceeds from the issuance of our Common Stock, $36.9 million of proceeds from the sale of Revenue Bonds, $14.9 million in proceeds on draws on our Revolving Credit Facility and a short-term borrowing from a related party, and $6.6 million in proceeds from the exercise of the RTI Global Warrants, Series A Warrants and private warrants during 2025. These cash inflows of $225.0 million from debt offerings in 2023 and proceeds of $38.0 million from related party debt, and cash outflows of $253.2 million paid in 2024 to purchase the outstanding revenue bonds were partially offset by $90 $28.7 million in payments on equipment financing leases, including the payoff of the entire outstanding balance of the CSC equipment financing payable, $14.9 million in payments on our Revolving Credit Facility and a short-term borrowing from a related party, $10.4 million in payments on related party revenue bonds, $8.7 million in debt and preferred transaction proceeds, $40 stock issuance costs paid, $4.9 million from sale of revenue bonds in payments to related parties, repurchase shares, and $8.0 $0.5 million from issuance of revenue bonds during 2024. in net payments on other financing activities.
Paragraph 65 · 48% changed
See Note 2 - Summary of Significant Accounting Policies in the Audited Notes to the Consolidated Financial Statements and Note 2 to the Audited Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K for more information about significant accounting policies and recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one, of their potential impact on our financial condition and our results of operations. pronouncements.
Paragraph 41 · 44% changed
On August 7, 2024, PCT LLC, Pure Plastic, and several other parties reached agreement on terms whereby certain investors purchased approximately $22.5 ▪Throughout 2025, we sold $41.9 million in aggregate par amount of Series A Bonds owned by PCT LLC at a purchase price of $800 $880 per $1,000 principal amount (the “August Purchased Bonds”) under a bond purchase agreement. The purchase agreement for net proceeds of the August Purchased Bonds was completed and funds received by PCT LLC on or about August 9, 2024, with $12.5 million in aggregate par amount being sold to Pure Plastic and $10.0 million in aggregate par amount being sold to other parties. $36.9 million.
Paragraph 51 · 40% changed
The $95.1 $47.5 million decrease increase in net cash used in investing activities for the year ending December 31, 2024 2025 compared to the same period in 2023 2024 was attributable to $27.0 $79.2 million lower held for sale investment purchases and $98.3 million lower capital expenditure payments, partially offset by $30.2 million of higher in maturities and sales of investments. investments during 2024 with no corresponding similar activity during 2025, partially offset by $17.0 million lower purchases of debt securities and $14.7 million lower capital expenditures. Our future capital requirements will depend on many factors, including the funding and construction schedule of the Thailand, Belgium and Augusta Facilities and build-out of additional Feed PreP facilities.
Paragraph 35 · 37% changed
The following is a summary of the components of our current liquidity. As of December 31, 2024, Restricted 2025, restricted cash consisted primarily of certain amounts held in a restricted escrow account related required to support outstanding letters of credit and other collateral, initial construction commitments for the Augusta purification facility project. Facility, and bond reserves for the Ironton Facility.
Paragraph 24 · 35% changed
The decrease in research Research and development expenses decreased approximately $0.6 million for the year ended December 31, 2025 as compared to the year ended December 31, 2024. This decrease was primarily due to $0.3 driven by $0.8 million decreased research of lower employee costs and development activities, $0.2 $0.1 million decrease in of lower operational site costs related to facilities used in research and development, costs, partially offset by $0.2 $0.3 million increase in rent and $0.1 million increase in employee costs related to of higher headcount of employees aligned to research and development activities.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors253 words changed in this paragraph; it is 41% similar to last year's version.
PCT is required to maintain compliance with certain financial and other covenants under its debt agreements. There are and will be operating and financial restrictions and covenants in certain of PCT’s debt agreements, including the Loan Agreement (as defined below), as well as and certain other agreements to which PCT is or may become a party. These limit, party, contain operating, financial covenants and other restrictions that, among other things, PCT’s or limit PCT and its subsidiaries’ ability to incur certain additional debt, create certain liens or other encumbrances, sell assets, and transfer ownership interests interests, pay dividends, and enter into transactions with affiliates of PCT. affiliates. These covenants limitations could also limit PCT’s ability to engage in restrict activities that may be in PCT’s best long-term interests. PCT’s failure, or perceived failure, interests and reduce its financial and operational flexibility. A failure to comply with certain covenants in these agreements could result in an Event event of Default (as defined therein) default under the various debt one or more agreements, allowing permitting lenders to accelerate the maturity for the debt under these agreements and to maturity, foreclose upon any on collateral securing the debt. An Event of Default would also adversely affect PCT’s ability to access its borrowing capacity debt, terminate commitments, or exercise other remedies. Cross-default provisions could compound these effects, and pay debt service on its outstanding debt, likely resulting in acceleration of such debt or in a default under other agreements containing cross-default provisions. Under such circumstances, PCT might not have sufficient funds or other resources to satisfy all of its obligations. In addition, the limitations imposed by PCT’s financing agreements on its ability to pay dividends, incur additional debt and to take other actions might significantly impair PCT’s ability to obtain other financing, generate sufficient cash flow from operations to enable PCT to pay its debt obligations or to fund other liquidity needs. Such consequences would adversely affect PCT’s business, financial condition, results of operations and prospects. refinance or restructure such indebtedness on favorable terms or at all.

Source: Item 1A, 10-K 0001193125-26-076801 vs Item 1A, 10-K 0000950170-25-028422

Accounting Policies166 words changed in this paragraph; it is 35% similar to last year's version.
In November 2024, December 2025, the Financial FASB issued ASU No. 2025-12, Codification Improvements to address suggestions received from stakeholders on the Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2024-04 – Debt – Debt with Conversion Codification (the "Codification") and Other Options: Induced Conversions to make other incremental improvements to U.S. GAAP. The update represents changes to the Codification that clarify, correct errors in or make other improvements to a variety of Convertible Debt Instruments, which improves the relevance and consistency in application of the induced conversion guidance in Subtopic 470-20, Debt-Debt with Conversion and Other Options. Specifically, the guidance is topics that are intended to clarify how make it easier to determine whether a settlement of convertible debt (particularly cash convertible instruments) at terms that differ from the original conversion terms should be accounted for under the induced conversion or extinguishment guidance. understand and apply. The amendments in to this update are effective for all entities for annual reporting periods fiscal years beginning after December 15, 2025, 2026 and interim reporting periods within those annual reporting periods. Early adoption The Company is permitted for all entities that have adopted the amendments in Update 2020-06. We are currently evaluating the impact that the updated standard will have on our its financial statements.

Source: Item 8, Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0001193125-26-076801 vs Item 8, Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0000950170-25-028422

Legal Proceedings159 words changed in this paragraph; it is 47% similar to last year's version.
On June 16, 2023, following unsuccessful efforts at mediating various disputes over certain unapproved change orders and payment applications, DB filed a demand for binding arbitration (“Arbitration Demand”) with the American Arbitration Association (“AAA”), seeking approximately $17.0 million plus attorney's fees and cost of the arbitration related to certain fee applications, change orders and amounts currently held in retainage by PCO, and, on June 21, 2023, filed a mechanics lien in Lawrence County, Ohio for the same sum. On July 20, 2023, PCO filed its Answer and Counterclaim, in which PCO contends that various deficiencies in DB’s work resulted in damages to PCO in excess of DB’s $17.0 million Arbitration Demand, including, but not limited to, the following: DB’s insufficient and incomplete engineering drawings and packages, insufficient and unorganized material management, insufficient and inefficient contractor management, insufficient and rudimentary schedule management, incomplete and inefficient procurement procedures, and that the Company was required to undertake significant re-work at additional cost resulting from DB’s failure to adequately perform its obligations under the EPC Contract. On September 14, 2023, DB filed a motion with the AAA seeking to join ThermalTech Engineering, Inc., and ThermalTech Turnkey Solutions LLC, a subcontractor engaged by DB to provide engineering services for the Ironton Project. In an order dated December 7, 2023, the AAA granted DB’s request to join ThermalTech Engineering, Inc., and ThermalTech Turnkey Solutions LLC.

Source: Item 3, via Note 13 – COMMITMENTS AND CONTINGENCIES, 10-K 0001193125-26-076801 vs Item 3, via Note 15 – COMMITMENTS AND CONTINGENCIES, 10-K 0000950170-25-028422

MD&A126 words changed in this paragraph; it is 60% similar to last year's version.
PureCycle Technologies, Inc. (“PCT” or “Company”) is We are a Florida-based corporation focused on commercializing a patented dissolution recycling technology to physically separate the polymer from other plastics, color, odors and contaminants impurities (the “Technology”), originally developed by The Procter & Gamble Company (“P&G”), for restoring waste polypropylene into resin, called PureFive™ PureFive® resin, which has similar properties and applicability for reuse as virgin polypropylene. PCT has We have a global license for the Technology from P&G. In April 2023, we certified P&G, which was amended during 2025 to permanently waive the Ironton Facility as mechanically complete. possible clawback of our exclusivity for plants located in North America and extend the time in which our plants must begin construction and commence sales in other regions to avoid a clawback of exclusivity under the license agreement. We expect to have capacity of approximately 107 million pounds per year when fully operational. Commissioning activities are ongoing, but the plant is not yet operating at the expected full capacity. PCT’s goal is to create introduced an important new segment of to the global polypropylene market that will assist multinational entities corporations in meeting their sustainability goals, goals as well as federal and state regulations and mandates, providing consumers with polypropylene-based products that are sustainable, and reducing overall polypropylene waste in the world’s landfills and oceans.

Source: Item 7, 10-K 0001193125-26-076801 vs Item 7, 10-K 0000950170-25-028422

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of PCT's Risk Factors and MD&A, 10-K Feb 26, 2026 against 10-K Feb 27, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
PCT relies principally on the commercialization of its PureFive® resin, and any other products PCT may develop in the future, to generate revenue growth. This includes establishing sales, marketing and distribution capabilities to effectively market and sell PureFive® resin products in the U.S., Europe, Asia, and in other territories; expanding the number of Purification plants and Feed PreP facilities; and maintaining and growing relationships with offtake partners, feedstock suppliers, customers, and other strategic partners. Achieving these objectives also requires procuring and maintaining all required regulatory approvals.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Market uncertainties, particularly related to demand for PureFive® resin, and any other products PCT may develop in the future, pricing dynamics and feedstock costs, make it difficult to predict the timing or amount of increased expenses or the timing, if ever, of achieving profitability. If demand for PureFive® resin products does not grow as anticipated, or if PCT cannot secure sufficient feedstock, offtake commitments or favorable pricing, revenue levels may not increase as expected. Even if adoption improves, adverse market conditions, cost pressures or execution risks may prevent PCT from generating sufficient revenue to achieve or sustain profitability. PCT currently has no other material lines of business or sources of revenue beyond PureFive® resin products, and this lack of diversification may limit its ability to adapt to changing business conditions and could adversely affect its business, financial condition, results of operations and prospects.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
vulnerability to market conditions, operational challenges, and changes in law or regulations. In addition, PCT’s ability to obtain additional financing for capital expenditures, and other needs may be impaired; by its existing debt and related covenants, as well as by general market conditions.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Capital project execution for larger projects is inherently complex. Project execution will likely impact PCT’s current and future earnings and ability to grow. If PCT is unable to achieve its scheduled and operability targets, this could result in a loss of stakeholder confidence and damage to its enterprise value.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
enforcement actions and securities litigation in the wake of a material cyber incident. Emerging artificial intelligence technologies may intensify these cybersecurity risks and introduce new governance and compliance obligations under evolving AI-related laws and guidance in the U.S. and abroad. In addition, PCT relies on third party software-as-a service and cloud providers for critical business functions, and any disruptions, misconfiguration or breach in these services could materially impact the Company's business. Increasing costs associated with cybersecurity protections may be costly and may also adversely affect the financial condition of PCT. While PCT attempts to mitigate these risks, PCT’s systems, data, networks, products, solutions and services remain potentially vulnerable to advanced and persistent cybersecurity threats.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
commercialization activities, PCT may not be able to further develop product candidates and PCT’s business, financial condition, results of operations and prospects may be materially and adversely affected.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
The use of PureFive® resin will also be subject to foreign regulatory schemes in Europe and Asia, including, but not limited to, the EC, the EFSA, the Federal Agency for the Safety of the Food Chain (the “FASFC”) in Belgium, the Association of Southeast Asian Nations (the “ASEAN”), and the Thai Food and Drug Administration (the “TFDA”) in Thailand. The EU has a general framework of rules for clearing and marketing food packaging materials through a positive list system as well as specific rules for recycled plastics. PCT is currently advancing the authorization process in Europe and hopes to receive the final authorizations in 2026.
Read it in 10-K Feb 26, 2026 at sec.gov
Show the other 62
AddedRisk Factors
In connection with the closing of the Business Combination (as defined below), holders of the Class A Units, Class B preferred Units, Class B-1 preferred Units and Class C Units of PCT LLC and the holders of such units, the “PCT Unitholders”) representing at least 70% of PCT LLC’s outstanding membership interests entered into the Investor Rights Agreement, whereby such PCT Unitholders agreed, with certain limited exceptions, to lock up the shares of Company's Common Stock they received in the Business Combination (the “IRA Lock-up”). On March 17, 2026, the IRA Lock-up will expire pursuant to its terms, and the PCT Unitholders will be able to sell the final 33.33% of such PCT Unitholder’s shares of the Company’s Common Stock (or 50% of such PCT Unitholder’s shares of the Company’s Common Stock with respect to certain affiliates of PCT LLC at the time of the Business Combination).
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Following the expiration of the IRA Lock-up, the PCT Unitholders will not be restricted from selling their shares of the Company’s Common Stock, other than by applicable securities laws. The timing or volume of sales or possible sales of these shares could have the effect of increasing the volatility in PCT’s share price or the market price of the Company’s shares of Common Stock could decline if a large amount of the Company’s shares of Common Stock are sold by the PCT Unitholders or if a large amount of the PCT Unitholders are perceived by the market as intending to sell the shares of Company Common Stock held by them. These sales, or the possibility that these sales could occur, may make it more difficult for the Company or its stockholders to sell equity securities in the future at a time and at a price that the Company or its stockholders deem appropriate.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
The conversion of some or all of the $250.0 million in aggregate principal amount of 7.25% Green Convertible Senior Notes issued on August 24, 2023 (the "Green Convertible Notes") or the Series B Convertible Perpetual Preferred Stock issued to certain investors pursuant to binding subscription agreements entered into on June 16, 2025 (the “Convertible Preferred Shares”) may dilute the ownership interests of PCT stockholders.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedRisk Factors
PCT relies principally on the commercialization of our PureFive™ resin to generate revenue growth. To date, such products and services have delivered minimal revenue. Also, PureFive™ resin product offerings and partnering revenues are in their very early stages. PCT believes that commercial success is dependent upon the ability to significantly increase the number of purification plants, feed pre-processing facilities (“Feed PreP facilities”), feedstock suppliers and offtake partners as well as strategic partners that utilize PureFive™ resin. PCT is an early commercial stage company that evaluates various strategies to achieve its financial goals and commercialization objectives on an ongoing basis. In this regard, PCT’s production methodology is subject to change as a result of modifications to business strategy, future plant designs and construction timelines, or market conditions. Furthermore, if demand for PureFive™ resin products does not increase as quickly as planned, PCT may be unable to increase revenue levels as expected. PCT is currently not profitable. Even if PCT succeeds in increasing adoption of PureFive™ resin products by target markets, maintaining and creating relationships with existing and new offtake partners, feedstock suppliers and customers, and developing and commercializing additional plants, market conditions, particularly related to pricing and feedstock costs, may result in PCT not generating sufficient revenue to achieve or sustain profitability.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
PCT’s ability to be profitable in the future will depend on PCT’s ability to commercially scale PureFive™ resin products and any other products PCT may develop in the future, including establishing sales, marketing and distribution capabilities to effectively market and sell PureFive™ resin products in the United States, Europe and in other territories and achieving market acceptance of PureFive™ resin products.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
PCT’s ability to be profitable will also depend on PureFive™ resin products maintaining regulatory approval and achieving market acceptance. Because of the uncertainties associated with market conditions, particularly related to pricing and feedstock costs, PCT is unable to accurately predict the timing or amount of increased expenses or when, or if, PCT will be able to achieve profitability. The amount of future losses will depend, in part, on the rate of future growth of PCT’s expenses and PCT’s ability to generate revenues.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
Many governments, regulators, investors, employees, customers and other stakeholders are increasingly focused on environmental, social and governance (“ESG”) and sustainability considerations relating to businesses, including climate change and greenhouse gas emissions, circularity, data privacy, artificial intelligence, human capital and diversity, equity and inclusion.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
The Company’s evolving efforts to develop, research, and accurately report on the implementation of a sustainability strategy may create operational risks and expenses and expose us to reputational, legal and other risks. While the Company makes statements about its ESG initiatives through information provided on its website, press statements, sustainability reports, and other communications, some of the statements may be based on hypothetical expectations and assumptions that may not be representative of current or actual risks or events or forecasts of expected risks or events, including related costs, and may not be accepted as sufficient by certain ESG-focused constituencies. Those assumptions and expectations involve risks and uncertainties, including those described under “Forward Looking Statements” and in the “Disclaimer” section in the Company’s Sustainability Reports, and may be subject to error or misinterpretation given the long timelines involved and the lack of an established single approach to identifying, measuring and reporting on many ESG matters. In addition, some stakeholders may disagree with the Company's targets and objectives, and the focus of stakeholders may change and evolve over time. The Company’s failure to adopt or comply with stakeholder expectations and standards on ESG matters, comply with applicable jurisdictional ESG laws and regulations, or meet sustainability goals or contribution targets that the Company sets), could result in legal and regulatory proceedings against the Company and materially adversely affect the Company’s business, reputation, results of operations, and financial condition.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
conversion of the Convertible Notes and/or the affiliate Convertible Notes could be used to satisfy short positions, or anticipated conversion of the Convertible Notes and/or the affiliate Convertible Notes into shares of PCT common stock could depress the price of PCT common stock.
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedRisk Factors
PCT may not be able to achieve full commissioning and the certification of operational performance required by an independent engineer of the Ironton Facility in the expected timeframe or at all due to a variety of factors, factors including, achieving but not limited to, the rates at which other plastics and additives can currently be removed from the Purification process, as well as challenges with sustaining continuous operations at full capacity over a number of the Ironton Facility and producing recycled pellets pursuant to certain specifications at nameplate capacity for five consecutive days.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
These limit, PCT’s debt agreements, including the Loan Agreement (as defined below), and certain other agreements to which PCT is or may become a party, contain operating, financial covenants and other restrictions that, among other things, PCT’s or limit PCT and its subsidiaries’ ability to incur certain additional debt, create certain liens or other encumbrances, sell assets, and transfer ownership interests interests, pay dividends, and enter into transactions with affiliates of PCT. affiliates.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
PCT’s failure, or perceived failure, A failure to comply with certain covenants in these agreements could result in an Event event of Default (as defined therein) default under the various debt one or more agreements, allowing permitting lenders to accelerate the maturity for the debt under these agreements and to maturity, foreclose upon any on collateral securing the debt. debt, terminate commitments, or exercise other remedies.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
The License Agreement sets forth certain construction and sales deadlines for future facilities outside North America America, which, if missed, could result in (i) a termination of the license granted under the License Agreement (if PCT is unable to make PureFive™ PureFive® resin at certain production volumes and at certain prices within a certain time frame). frame) or (ii) conversion of the license to a non-exclusive license (if PCT is unable or unwilling to provide P&G with PureFive® resin at certain prices from the first plant).
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
There is also a risk that significant unanticipated costs or delays could arise due to, among other things, errors or omissions, unanticipated or concealed construction site conditions, including subsurface conditions, unforeseen technical issues or increases in plant and equipment costs, insufficiency of water supply and other utility infrastructure, or inadequate contractual arrangements.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
In addition, PCT will be subject to additional regulatory regimes upon expanding to new regions, including foreign regulatory authorities in the European Union EU, such as the European Commission, EC, the European Food Safety Authority, EFSA, and the FASFC, foreign regulatory authorities in the ASEAN such as the TFDA, and similar regulatory authorities elsewhere, such as in Asia. authorities.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
If PCT fails to enter into collaborations and does not have sufficient funds or expertise to undertake the necessary development and commercialization activities, PCT may not be able to further develop product candidates and PCT’s business, financial condition, results of operations and prospects may be materially and adversely affected.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
The failure to obtain timely customer approval and extended delays in customers’ adoption of PCT’s PureFive™ as a substitute for a customer’s existing polypropylene supplies may have a material adverse effect on PCT’s business, financial condition, results of operations and prospects. PureFive® resin
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Issuing additional shares of PCT’s common stock Common Stock or other equity securities or securities convertible into equity may dilute the economic and voting rights of PCT’s existing stockholders or reduce the market price of PCT’s common Common Stock, or both, and could be constrained by stock exchange rules that may require prior stockholder approval for certain large or both. below-market issuances.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
PCT’s existing and future debt service obligations obligations, together with restrictions in its financing arrangements and the uncertainty of access to additional capital, could have important consequences to PCT for the foreseeable future, including the following: future.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
If PCT fails to comply with such requirements on an ongoing basis, PCT may be subject to fines or other penalties, or may be prevented from selling PureFive™ resin products, and PCT’s business, financial condition, results of operation and prospects may be harmed.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
A Ultimately, the loss of the managers or key employees, or their failure to satisfactorily perform their responsibilities, high caliber and high potential team members could have an adverse effect on PCT’s business, financial condition, results of operations and prospects.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
PCT may not be able to attract, develop and maintain the skilled workforce necessary to operate its business, and labor expenses may increase as a result of a shortage in the supply of qualified personnel, which will may negatively impact PCT’s business, financial condition, results of operations and prospects.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
During 2025, we completed various capital raises to fund operations and to fund future capital requirements for facilities expansion. In February 2025, we entered into subscription agreements (the "Offering") with certain investors in a private placement for an aggregate of 4,091,293 shares of our Common Stock at a price of $8.0655 per share. The gross proceeds from the Offering were approximately $33.0 million, before deducting fees and other estimated offering expenses. Further, during 2025, we sold $41.9 million in aggregate par amount of Southern Ohio Port Authority Exempt Facility Revenue Bonds (PureCycle Project), Tax-Exempt Series ("Series A Bonds") owned by PCT LLC at a price of $880 per $1,000 principal amount under a bond purchase agreement, for net proceeds of $36.9 million.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
In June 2025, we sold $300.0 million in aggregate amount (before deducting placement agent fees and other offering expenses) of Series B Convertible Perpetual Preferred Stock, par value $0.001 per share (the “Series B Convertible Perpetual Preferred Stock”) to various investors, including related parties, in a private placement transaction.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
•We announced that we will begin construction of a 130 million pound per year polypropylene recycling facility in Thailand (the "Thailand Facility"). We will be working with IRPC Public Company Limited ("IRPC") at IRPC’s eco-industrial zone in Rayong, Thailand. IRPC is an integrated petrochemical operator in Southeast Asia. Its production structure comprises petroleum and petrochemical complexes, complete with utilities and infrastructure supporting the operations, including a deep-sea port, oil depots and power plants. We intend to leverage this existing site infrastructure to reduce the costs of certain construction activities. The permitting process has begun for this site, and the Thailand Facility is expected to become operational in late 2027.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
•We also plan to construct a 130 million pound per year polypropylene recycling facility at our Antwerp, Belgium site (the "Belgium Facility"). We are currently drafting the permit application in Belgium and plan to submit our permit application with the relevant authorities (Province of Antwerp) in 2026. The Belgium Facility is projected to become operational in mid to late 2028.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
•We have modified our original plans for the facility in Augusta, Georgia (the "Augusta Facility") to build a single-line Purification facility, designed to produce 300 million pounds per year of recycled polypropylene. The design of the larger Purification facility is in process and will incorporate learnings from our Ironton Facility. The Augusta Facility is planned to be integrated with pre-processing ("PreP") and compounding assets. We expect to have the expanded Purification line at the Augusta Facility operational by 2030. It is possible that additional, scaled-up lines could be added to the Augusta Facility at a later date.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
During 2025, we received additional FDA LNOs, which expand upon previous LNOs and allows our PureFive® resin to be produced under a broader range of process conditions. These broader conditions allow for greater flexibility and reduced energy usage in the Purification process. Subject to operating under these process conditions, our resin can be used in articles in contact with all types of food under FDA’s COU "A" (“high temperature heat-sterilized”) through "H" (“frozen or refrigerated storage: ready-prepared foods intended to be reheated in containers at time of use”), provided the feedstock comes from food-contact articles and complies with all applicable authorizations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Our revenue is primarily generated from the sale of recycled and compounded polypropylene resin pellets or co-products to customers. Those sales predominantly contain a single performance obligation and revenue is recognized at the point in time when control of the product is transferred to customers, along with the title, risk of loss and rewards of ownership. Depending on the arrangement with the customer, these criteria are met either at the time the product is shipped or when the product is made available or delivered to the destination specified in the agreement with the customer. Net sales revenue is recognized on the net amount expected to be received by the Company from the customer.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Selling, general and administrative expense consists primarily of personnel-related expenses for our corporate, executive, finance and other administrative functions and professional services, including legal, audit and accounting services. Costs attributable to the design and development of the Feed PreP and Purification facilities are capitalized and, when placed in service, depreciated over the expected useful life of the asset through selling, general and administrative expense. We expect our selling, general, and administrative expenses to increase for the foreseeable future as we scale headcount with the growth of our business and build future Purification-related facilities.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
The Company reported approximately $8.4 million and no revenues during the years ended December 31, 2025 and 2024, respectively. The Company is currently in various stages of customer application trials, which is anticipated to generate revenue growth in future periods.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Cost of operations increased approximately $23.6 million for the year ended December 31, 2025 as compared to the year ended December 31, 2024. Cost of operations for the year ended December 31, 2025 included approximately $16.3 million of higher production-related costs due to the ramp-up in production that occurred during the year, a $3.7 million loss on disposal of fixed assets, and $3.1 million of higher facilities costs attributable to the opening of our Feed PreP facility in Denver, Pennsylvania in September of 2024, and the expansion of offsite storage and processing space.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedMD&A
•Feed Pre-Processing (“Feed PreP”) collects, sorts, and prepare polypropylene waste (“feedstock”) for purification. The purification step is a dissolution process that uses a combination of solvent, temperature, and pressure to return the feedstock to near-virgin condition through a novel configuration of commercially available equipment and unit operations.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
The FEU is an 11,000 square foot facility located adjacent to the commercial line at the Ironton Facility with over 1 mile of stainless-steel piping. The facility was completed in July 2019 and has been producing PureFive™ resin since that time. The FEU is considered a pilot scale replica of the larger commercial line at the Ironton Facility.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
Located on the same site as the FEU, PCT commenced construction in October 2020 of its first commercial-scale plant, the Ironton Facility. PCT commenced commissioning activities at the Ironton Facility in April 2023, and later in 2023, PCT achieved mechanical completion of the plant and commenced pellet production from post-industrial and post-consumer materials. The Ironton Facility is expected to have PureFive™ resin capacity
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
of approximately 107 million pounds per year when fully operational. While the facility is currently operational, PCT is pacing production with the level of anticipated commercial sales, while working on improving reliability and product quality. During 2024, the Company initiated compounding operations to blend its resin with either post-industrial recycled material or virgin polypropylene, which is expected to improve product consistency and accelerate the product delivery to customers. Currently, PCT is focused on customer sampling and qualifications and believes that this will lead to meaningful future sales.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
PCT has experienced intermittent mechanical challenges during the commissioning process including, but not limited to, limits in the rates at which certain contaminants can currently be removed from the purification process, as well as challenges with sustaining continuous operations. Recently, PCT has been focused on the recovery and removal of polyethylene and other solids (“CP2”), which impacts the ability to run higher volumes and produce consistent, high quality PureFive™ resin. PCT has modified the CP2 removal system to remove higher volumes of CP2 more quickly and believes these changes enable us to produce higher volumes of on-spec product. The Company is currently testing the system improvements at various operating conditions to validate the new limits.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
The lease for the Company's research and development lab in Durham, North Carolina commenced in 2023 and the facility opened in 2024. The lab is instrumental in developing cutting-edge analytical techniques to characterize polymer-solvent interaction in supercritical fluids, advancing fundamental process understanding to target hard to recycle polypropylene materials, generating insights into process modifications that drive energy reduction and capital expenditure reductions for future plant sites, leveraging research and development analytical techniques and expertise to allow industries with traditionally low recycling rates to adopt recycled polypropylene material, and supporting zero-waste efforts by engaging third parties to utilize Co-Product 1 and CP2.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
In July 2021, PCT reached an agreement with the Augusta Economic Development Authority (“AEDA”) to build its first U.S. facility with multiple lines for both Feed PreP and purification (“multi-line facility”) in Augusta, Georgia (the “Augusta Facility”). PCT expects the approximately 200-acre location to eventually include up to eight production lines, which are expected to collectively have PureFive™ resin production capacity of approximately 1 billion pounds per year. When fully operational, each purification line at the Augusta Facility is expected to have annual production capacity of approximately 130 million pounds of PCT’s PureFive™ resin. PureCycle has allocated 40% of the Augusta Facility output for Lines 1 and 2 to existing customers and expects that additional offtake agreements will continue to be negotiated.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
On June 30, 2023, PCT and the AEDA executed an Economic Development Agreement (“EDA”) related to the Company’s plans to construct the Augusta Facility. Pursuant to the AEDA, PCT expects to receive certain property tax abatement benefits as well as certain other incentives, including site infrastructure development assistance (“Incentive Benefits”). In order to receive the Incentive Benefits under Phase One (as defined below) of the Augusta Project, PCT will be obligated to create 82 full-time jobs with investments of at least $440 million no later than December 31, 2026. Through December 31, 2024, PCT has invested approximately $114.0 million for pre-construction engineering and long-lead equipment for the benefit of Phase One investments. If PCT elects to activate the second phase of the Augusta Project, PCT will be required to create an additional 25 full-time jobs and investments of $295 million no later than December 31, 2028. To the extent PCT fails to achieve an average of 80% of the jobs and investment commitments in any year over the 20-years of each phase, PCT will be required to make a repayment to the AEDA of a pro rata portion of the total value of the Incentive Benefits received by PCT in such year.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
Also on June 30, 2023, PCT entered into a series of agreements with the AEDA to construct phase one (“Phase One”) of the Augusta Facility. PCT is leasing 150 acres of land (“Real Property”) owned by the AEDA and will construct buildings, building equipment, and other structures (the “Improvements”) on the land. PCT will also acquire and install the necessary processing, warehousing, and other equipment, as well as conveyors and pipelines (the “Equipment”, together with the Real Property and the Improvements, the “Augusta Project”). The Improvements and Equipment will be transferred to the AEDA and leased back by PCT. As noted above, PCT anticipates that the first portion of Phase One will consist of one purification line. Also as noted above, construction of the first purification line must be completed by December 31, 2026.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
The legal sale-leaseback structure provides the Incentive Benefits to PCT as lessee of the Augusta Project. PCT will remain the owner of the Improvements and Equipment for accounting purposes during the term of the lease as PCT will have the right to acquire title to the Augusta Project for a nominal amount during the term and at the conclusion of the arrangement, which has an initial expiration date in 2044. The payments PCT makes to the AEDA during the term of the arrangement are not otherwise expected to be material.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
In November 2024, the Company commenced early works construction activities including site clearing and grading. When early works are successfully completed, expected next steps should include underground utility installation, piling, and foundations. Pursuant to the EDA, PCT must continue construction progress on the first purification line under the first phase of the Augusta Project during 2025 or risk losing certain future Incentive Benefits. While the Company believes it has satisfied the contractual obligations regarding financing and construction of Phase One to date, the AEDA believes that it could seek to terminate the lease if PCT does not demonstrate further progress on Phase One. Market conditions remain challenging and have created uncertainty as to the timing or likelihood of success of the currently anticipated project financing for the Augusta Facility. As a result, PCT is currently pursuing various structures for project financing of the Augusta Facility. While PCT remains confident in its ability to finance the Augusta Facility, it is limiting its expenses and adjusting its timeline in light of this uncertainty. If PCT is unable to raise additional debt or equity, when desired, or on terms favorable to PCT, PCT’s business, financial condition, and results of operations would be adversely affected.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
PCT sees a robust pipeline of demand for its recycled polypropylene and PCT is seeing market acceptance of its “Feedstock+” pricing model for its PureFive™ resin. The Feedstock+ pricing model divides the market cost of feedstock by a set yield-loss and adds a fixed price, which effectively passes on the cost of feedstock and de-risks PCT’s operating margin volatility.
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedMD&A
The $95.1 $47.5 million decrease increase in net cash used in investing activities for the year ending December 31, 2024 2025 compared to the same period in 2023 2024 was attributable to $27.0 $79.2 million lower held for sale investment purchases and $98.3 million lower capital expenditure payments, partially offset by $30.2 million of higher in maturities and sales of investments. investments during 2024 with no corresponding similar activity during 2025, partially offset by $17.0 million lower purchases of debt securities and $14.7 million lower capital expenditures.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The $95.1 $2.1 million decrease in net cash used in investing operating activities for the year ending December 31, 2024 2025 compared to the same period in 2023 2024 was primarily attributable to $27.0 million lower held for sale investment purchases and $98.3 million lower capital expenditure payments, cash interest payments during the year, partially offset by $30.2 million of a net increase in higher maturities operating costs and sales of investments. changes in working capital.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The Company’s Our FDA food contact grades are food-contact grade resins are, subject to certain conditions, capable of being used for all food types per the conditions of use COUs listed and per all applicable authorizations in the food contact regulations listed in the 21 CFR (Code of Federal Regulations, Title 21). regulations.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
We expect our research Research and development expenses to increase for the foreseeable future as we increase investment in feedstock evaluation, including investment in include evaluation of new front-end feedstock mechanical separators to improve feedstock purity and increase the range of feedstocks PCT we can process economically.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
PCT’s goal is to create We have introduced an important new segment of to the global polypropylene market that will assist multinational entities corporations in meeting their sustainability goals, goals as well as federal and state regulations and mandates, providing consumers with polypropylene-based products that are sustainable, and reducing overall polypropylene waste in the world’s landfills and oceans.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Note that while While certain legally binding legally-binding offtake arrangements have been entered into with customers, these arrangements are not unconditional and definite agreements subject only to customer closing conditions, and do not qualify as off-balance sheet arrangements required for disclosure.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. reasonable.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
PCT’s Our future capital requirements will depend on many factors, including the funding mechanism and construction schedule of the Thailand, Belgium and Augusta Facility and other anticipated facilities outside the United States, Facilities, build-out of additional Feed PreP facilities, funding needs to support other business opportunities, funding for general corporate purposes, debt service, and other challenges or unforeseen circumstances.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” section contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 2024 for the results of operations cash flows discussion for the fiscal year ended December 31, 2023 2024 compared to the fiscal year ended December 31, 2023.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
(“PCT” or “Company”) is We are a Florida-based corporation focused on commercializing a patented dissolution recycling technology to physically separate the polymer from other plastics, color, odors and contaminants impurities (the “Technology”), originally developed by The Procter & Gamble Company (“P&G”), for restoring waste polypropylene into resin, called PureFive™ PureFive® resin, which has similar properties and applicability for reuse as virgin polypropylene.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The Company is We are conducting additional testing and plans plan to make further LNO submissions for additional post-consumer recycled feedstock sources and expanded Conditions of Use. COUs.
Read it in 10-K Feb 26, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PCT/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.